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Background: Previously, we had identified a specific whole blood–derived microRNAs (miRNAs) signature in mice
following in vivo injection of lipopolysaccharide (LPS) originated from Gram-negative bacteria. This study was
designed to profile the circulating miRNAs expression in mice exposed to lipoteichoic acid (LTA) which is a major
component of the wall of Gram-positive bacteria.
Results: C57BL/6 mice received intraperitoneal injections of 100 μg of LTA originated from Bacillus subtilis,
Streptococcus faecalis, and Staphylococcus aureus were killed 6 h and the whole blood samples were obtained for
miRNA expression analysis using a miRNA array (Phalanx miRNA OneArrayW 1.0). Up-regulated expression of miRNA
targets in the whole blood, serum and white blood cells (WBCs) of C57BL/6 and Tlr2−/− mice upon LTA treatment
in 10, 100, or 1000 ug concentrations was quantified at indicated time (2, 6, 24, and 72 h) using real-time RT-PCR
and compared with that in the serum of C57BL/6 mice injected with 100 ug of LPS. A significant increase of 4
miRNAs (miR-451, miR-668, miR-1902, and miR-1904) was observed in the whole blood and the serum in a
dose- and time-dependent fashion following LTA injection. Induction of miRNA occurred in the serum after 2 h
and persisted for at least 6 h. No increased expression of these 4 miRNAs was found in the WBCs. Higher but not
significant expression level of these 4 miRNAs were observed following LTA treatment in the serum of
Tlr2−/−against that of C57BL6 mice. In contrast, LPS exposure induced moderate expression of miR-451 but not of
the other 3 miRNA targets.
Conclusions: We identified a specific circulating miRNA signature in mice exposed to LTA. That expression profile is
different from those of mice exposed to LPS. Those circulating miRNAs induced by LTA or LPS treatment may serve
as promising biomarkers for the differentiation between exposures to Gram-positive or Gram-negative bacteria.
Keywords: MicroRNAs, Lipoteichoic acid, Lipopolysaccharide, Toll-like receptor, Gram-positive bacteria,
Gram-negative bacteria, MicroarrayBackground
MicroRNAs (miRNAs) are small non-coding, endogenous,
single-stranded RNA molecules that regulate the activity
of specific mRNA targets and play important roles in a
wide range of physiologic and pathologic processes [1,2].
Alteration of miRNA expression profiles has been
observed in various diseases and help distinguish between
disease states [3]. Identification of these multiple miRNA* Correspondence: m93chinghua@gmail.com
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reproduction in any medium, provided the orchanges is valuable because specific signatures of miRNA
combinations unique to a normal physiological or patho-
logical state can serve as an useful reference [4]. Recently,
biochemical analyses indicate that miRNAs are resistant
to RNase activity, extreme pH and temperature, extended
storage, and large numbers of free-thaw cycles [5,6]. In
addition, extracellular miRNAs circulate in the blood are
remarkably stable [7], albeit there is presence of ribonucle-
ase in both plasma and serum [8,9]. With the possibility to
analyze multiple miRNAs in parallel to increase sensitivity
and specificity by using complex miRNA expression pat-
terns, miRNAs might constitute very useful and accessible
diagnostic tools in a cluster pattern [5,10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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venting further complications. Pathological processes after
bacterial infection are mainly induced by structural com-
ponents of bacterial cell walls [11]; In Gram-negative
bacteria, these components are lipopolysaccharide (LPS)
[12] and in Gram-positive flora, these components are
represented by lipoteichoic acid (LTA) [13]. The appear-
ance of LPS and LTA in the blood leads to activation of
multiple intracellular signaling pathways necessary for the
rapid change of the target cell functional state to provide
an efficient innate immune response depends on Toll-like
receptor 4 (TLR4) and Toll-like receptor 2 (TLR2),
respectively. Previously, we had identified a specific whole
blood–derived miRNA signature in mice exposed to LPS
as there was a dose- and time-dependent upregulated ex-
pression of the miRNA targets (let-7d, miR-15b, miR-16,
miR-25, miR-92a, miR-103, miR-107 and miR-451) follo-
wing in vivo LPS injection [14]. The above-mentioned 8
miRNAs was evident as early as 2 h and persisted for at
least 6 h following injection with 100 ug of LPS. In
contrast, LTA exposure induced moderate expression of
miR-451 but not of the other 7 miRNA targets [14].
Seeing these circulating miRNAs may serve as promis-
ing biomarkers for the differentiation between in vivo
exposure to LPS or LTA. The present study was designed




C57BL/6 mice were purchased from BioLasco (Taiwan).
Tlr2−/− (B6.129-Tlr2tm1Kir/J) mice were purchased
from Jackson Laboratory (Bar Harbor, ME, USA). All
housing conditions were established and surgical proce-
dures, analgesia, and assessments were performed in an
AAALAC-accredited, SPF facility following national and
institutional guidelines. Animal protocols were approved
by the IACUC of Chang Gung Memorial Hospital. LTA
from different Gram-positive bacteria, including Bacillus
subtilis (catalog no. L3265), Streptococcus faecalis (L4015),
and Staphylococcus aureus (L2515) as well as LPS from
different Gram-negative bacteria, including Escherichia
coli serotype 026:B6 (L3755), Klebsiella pneumonia
(L1519), Salmonella enterica serotype Enteritidis (L6761),
Serratia marcescens (L6136), and Pseudomonas aeruginosa
(L9143) were purchased from Sigma (St. Louis, MO,
USA). When the mice gained a weight of 20–35 g and be-
came 4–6 weeks old, they were intraperitoneally injected
with 10, 100, 1000 μg of LTA reconstituted in 100 μL of
phosphate-buffered saline (PBS). Animals were sacrificed
at 2, 6, 24, and 72 h after LPS injection. The control group
was injected with 100 μL PBS. Whole blood was drawn
for miRNA expression analysis. For comparison, intraperi-
toneal injections of 10, 100, 1000 μg of LPS fromEscherichia coli serotype 026:B6 (L3755) were performed
in C57BL/6 mice, that were killed 6 h after injection and
the whole blood was obtained for quantification of miRNA
expression.RNA isolation and preparation
In brief, coagulated whole blood samples (1 mL per
mouse) were collected at indicated times of experiment.
After incubating the whole blood at 37°C for 1 h and
centrifugating at 3,000 rpm for 10 min, the white blood
cells (WBCs) were slowly removed from the correspond-
ing layers and the serum was extracted and stored at
−80°C before use. Total RNA was extracted from whole
blood, serum and WBCs by using the RNeasy Mini kit
(Qiagen, Hilden, Germany). Purified RNA was quanti-
fied by measuring the absorbance at 260 nm by using
an SSP-3000 Nanodrop spectrophotometer (Infinigen
Biotechnology, Inc., City of Industry, CA, USA). For
miRNA array analyses, the quality of purified RNA was
assessed using a Bioanalyzer 2100 (Agilent Technolo-
gies, Santa Clara, CA, USA). Total RNA (2 μg) was
reverse transcribed into cDNA by using the TaqMan
miRNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA). Target miRNA was reverse tran-
scribed using sequence-specific stem-loop primers.
miRNA cDNA (10 ng) for each target was used for real-
time PCR.miRNA microarray analysis
Mouse genome-wide miRNA microarray analysis was per-
formed by Phalanx Biotech with the Mouse & Rat miRNA
OneArrayW 1.0 (Phalanx Biotech Group, Hsinchu, Taiwan)
contains a total of 2,319 probes, including 135 experimen-
tal control probes and 728 unique miRNA probes from
mouse and 348 from rat (miRBase Release 12.0). Briefly,
fluorescent targets were prepared from 2.5-μg total RNA
samples by using the miRNA ULS™ Labeling Kit (Kreatech
Diagnostics, Amsterdam, Netherlands). Labeled miRNA
targets enriched using NanoSep 100K (Pall Corporation,
Port Washington, NY, USA) were hybridized to the
microarray with Phalanx hybridization buffer by using
the OneArrayW Hybridization Chamber. After overnight
hybridization at 37°C, non-specific binding targets were by
3 washing steps (Wash I: 37°C, 5 min; Wash II: 37°C,
5 min and 25°C, 5 min; and Wash III: rinse 20 times). The
slides were dried by centrifugation and scanned using
Axon 4000B scanner (Molecular Devices, Sunnyvale, CA,
USA). The Cy5 fluorescent intensities of each spot were
analyzed using GenePix 4.1 software (Molecular Devices).
The signal intensity of each spot was processed using the
R program. We filtered out spots for which the flag was
<0. Spots that passed the criteria were normalized using
the 75% scaling normalization method. Normalized spot
Figure 1 Hierarchical cluster analysis of significant expression of miRNA in whole blood of C567BL/6 mice 6 h after injection of 100-μg
LPS or LTA, originated from different Gram-negative and Gram-positive bacteria, respectively. The indicated miRNA name by the
corresponding gene probe in Phalanx array could be found in: http://www.phalanx.com.tw/Products/MRmiOA_Probe.php. Kleb: Klebsiella
pneumonia; Salmo: Salmonella enterica serotype Enteritidis; Serra: Serratia marcescens; Pseudo: Pseudomonas aeruginosa; Bacl: Bacillus subtilis;
Strep: Streptococcus faecalis; Staph: Staphylococcus aureus; Contr: sham control with PBS injection.
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http://www.jbiomedsci.com/content/20/1/2intensities were converted into gene expression log2 ratios
for the control and treatment groups. Spots with log2
ratios ≥ 1 or log2 ratio ≤ −1 and P-value < 0.05 are ana-
lyzed further. These differentially expressed miRNAs were
subjected to hierarchical cluster analysis using average
linkage and Pearson correlation as a measure of similarity.
The GEO accession number for the microarray data is
GSE41837.
Quantification of miRNA expression
The miRNA expression of the whole blood, serum and
WBCs was quantified by real-time RT-PCR using Applied
Biosystems 7500 Real-Time PCR System (Applied Biosys-
tems) to verify the miRNA targets with up-regulated ex-
pression that were detected through the miRNA array
from whole blood following injection of LTA different
doses (10, 100, and 1000 μg) or at indicated survival times
(2, 6, 24, and 72 h). Expression of the miRNAs in serum
following intraperitoneal injections of LPS at doses of 10,
100, and 1000 μg were measured for comparison. Expres-
sion of each miRNA of the whole blood samples or WBCs
was represented relative to the expression of U6 small nu-
clear RNA (U6 snRNA) as an internal control. For the
serum, 25 fmol of single stranded cel-miR-39 synthesized
by Invitrogen (Carlsbad, CA 92008) were spiked into 400
μL of serum an internal control for the expression of each
miRNA. We calculated the fold-expression of induction as
the relative expression value obtained from 6 samples in
comparison with that from the control group. Intergroup
group comparisons were performed using analysis of
variance (ANOVA) and an appropriate post hoc test to
compensate for multiple comparisons (SigmaStat; Jandel,
San Rafael, CA, USA). P-values < 0.05 were considered
significant.
Results
Up-regulated miRNA targets in microarray analysis
Expression of miRNA was considered significantly differ-
ent when values for all samples from the whole blood of
experimental mice at 6 h after 100 μg LTA or LPS injec-
tions were more than double of those for the controls
(n=3 for each subgroup). The hierarchical cluster ana-
lysis of all significant miRNAs is shown in Figure 1,
which illustrates miRNAs differentially expressed in the
whole blood after LTA or after LPS injection. Unsuper-
vised hierarchy clustering was used to separate the LTA-
or LPS-treated samples into different groups. LTA from
Bacillus subtilis (L3265) demonstrated a different ex-
pression to those from Streptococcus faecalis (L4015)
and Staphylococcus aureus (L2515) in the unsupervised
hierarchy clustering (Figure 1). The up-regulated miRNA
targets more than double of those of the control is
shown in Table 1. There were 4 miRNAs (miR-451,
miR-668, miR-1902, and miR-1904) showed significantlyincreased expression in the whole blood of mice exposed
to LTA originated from different Gram-positive bacteria.
Expression profiles of miRNAs
Expression of miRNAs in whole blood, serum and WBCs
following LTA injection was quantified using real-time
RT-PCR to verify selected up-regulated miRNA targets
with at least 2-fold increase in expression (miR-451, miR-
668, miR-1902, and miR-1904). In the whole blood,
following injection with 10 μg of LTA, there was signifi-
cantly increased expression in miR-1902, but not in
miR-451, miR-668 or miR-1904 (Figure 2A). Upon 100 ug
of LTA injection, significantly increased expression around
2- to 3-fold was observed in miR-451, miR-1902, and
miR-1904, but not in miR-668 (Figure 2A). When exposed
to 1000 ug of LTA, all these four miRNAs (miR-451,
miR-668, miR-1902, and miR-1904) had a significant ex-
pression around 3- to 6-fold than the control (Figure 2A).
Induction of miR-451, miR-1902, and miR-19042, but not
miR-668, was evident at 6 h following injection with 100
ug of LTA (Figure 2B). At 24 h, only miR-451 continued to
be significantly expressed in the whole blood (Figure 2B).
No up-regulation of these 4 miRNA targets was detected at
2 h as well as 72 h after LTA injection (Figure 2B).
In the serum, the dose- and time-dependent pattern of
expression of these 4 miRNAs following LTA injection is
similar to those in the whole blood, except that signifi-
cantly increased expression of miR-1904 was found
following injection with 10 μg of LTA (Figure 3A) and
induction of miR-1902 and miR-19042 was evident as
early as at 2 h following injection with 100 ug of LTA
(Figure 3B). In addition, at 24 h, only miR-1902, but not
miR-451 which was observed in the whole blood, contin-
ued to be significantly expressed in the serum (Figure 3B).
No up-regulation of these 4 miRNA targets was detected
in the serum at 72 h after LTA injection (Figure 3B).
miRNA expression in the serum and WBCs in C57BL/6
and Tlr2 knockout mice
In contrast to the expression of miR-451, miR-1902,
miR-1904, but not miR-668, in serum of C57BL/6 at 6 h
after exposure to 100 μg of LTA, no significantly up-
regulation of these 4 miRNA targets was detected in the
WBCs after LTA injection, when compared with those in
C57BL/6 receiving PBS injection (Figure 4A). In Tlr2−/−
mice, significantly higher expression of miR-451, miR-668,
miR-1902, and miR-1904 in the serum were observed fol-
lowing LTA injection with around 6- to 10-fold of expres-
sion against that from the Tlr2−/− mice injected with PBS
(Figure 4B). Notably, higher expression of these 4 miRNA
targets in the serum of Tlr2−/− mice was noted after LTA
injection than those in the serum of C57BL/6 mice, albeit
not statistically significant (Figure 4C). No significant
change of these 4 miRNA targets was detected in the
Table 1 Up-regulated miRNA targets more than double of those from the controls in microarray analysis of the whole
blood of experimental mice at 6 h after the injection of 100 μg of LTA from Bacillus subtilis, Streptococcus faecalis, and
Staphylococcus aureus (n=3 for each subgroup)
LTA induced miRNA targets Bacillus subtilis Streptococcus faecalis Staphylococcus aureus
miR-451 1.22 1.54 1.25
miR-668 1.52 1.06 1.14
miR-1902 1.37 1.44 1.05
miR-1904 1.27 1.61 1.01
The value is expressed as fold (log2) of the miRNA targets expression than those in the control.
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jection (Figure 4C).
miRNA expression after LPS injection
To investigate that whether LPS originating from Gram-
negative bacteria Escherichia coli serotype 026:B6 (L3755)
induces expression of miR-451, miR-668, miR-1902, and
miR-1904, the serum was obtained for real-time PCR at
6 h following intraperitoneal injections of 10, 100, orFigure 2 (A) Dose- and (B) time-dependent upregulation of miRNA ex
of the up-regulated miR-451, miR-668, miR-1902 and miR-1904 identified u
following injection of 10, 100, 1000 μg of LTA; mice were killed at the indic
injection. Bars represent means ± SEM of 6 experiments; *, P < 0.05 vs. con1000 μg LPS. The results showed that LPS significantly
induced miR-451 expression at concentrations of 10, 100
and 1000 μg but not up-regulated the expression of the
other 3 miRNA targets (Figure 5).
Discussion
While LPS and LTA induce similar inflammatory
responses, the signaling and sensing of LPS and LTA dif-
fer significantly. In previous study, we had demonstratedpression in the whole blood. Using real-time RT-PCR, the expression
sing miRNA microarray was detected in the whole blood at 6 h
ated survival times (2, 6, 24, and 72 h) following 100 μg of LTA
trol.
Figure 3 (A) Dose- and (B) time-dependent upregulation of miRNA expression in the serum. Using real-time RT-PCR, the expression of the
up-regulated miR-451, miR-668, miR-1902 and miR-1904 was detected in the serum at 6 h following injection of 10, 100, 1000 μg of LTA; mice
were killed at the indicated survival times (2, 6, 24, and 72 h) following 100 μg of LTA injection. Bars represent means ± SEM of 6 experiments;
*, P < 0.05 vs. control.
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miR-16, miR-25, miR-92a, miR-103, miR-107, and miR-
451) is significantly altered in the whole blood of mice
after exposure to LPS in a dose- and time-dependent
fashion [14]. Besides, LTA did not up-regulate the
expression of these miRNA targets, except miR-451, in
the concentration up to 1000 ug [14]. In this study, we
demonstrated that expression of miR-451, miR-668,
miR-1902, and miR-1904 is significantly altered in the
whole blood and serum of mice after exposure to LTA in
a dose- and time-dependent fashion. Additionally, LPS
significantly induced miR-451 expression at concentra-
tions of 10, 100 and 1000 μg but not increase the ex-
pression of the other 3 miRNA targets. Therefore, a
specific signature of miRNAs in the circulation of mice
exposed to LPS and LTA may serve as promising as bio-
markers for their exposure.
Among these 4 miRNA targets, miR-451 had been
reported to be a promising biomarker for microRNAs
involved in lung tissue infected with pathogen asActinobacillus pleuropneumoniae [15]. miR-451 had also
been found to direct a negative regulatory cascade to
tune the cytokine production of dendritic cells including
IL-6, TNF, CCL5/RANTES, and CCL3/MIP1α [16].
However, miR-451 also presents with a significant level
in RBCs and comprised the major source of variation in
its level measured in the circulation and deterred its use
as a circulating biomarker [17]. Up-regulation miR-668
in the peripheral blood of mice exposed to mainstream
smoking had been found to reflect the dynamic patho-
logical changes in smoking-related interstitial fibrosis
[18], but so far there was no linkage of miR-668 to any
infectious disease had been reported in the literature.
Notably, miR-451 was both induced by LPS and LTA
treatment in this study and the expression of miR-668
was significantly induced in the whole blood and in the
serum by the high dose of LTA in 1000 ug concentra-
tion, but not by lower to medium dose of LTA in 10 and
100 ug concentrations. Therefore, the use of miR-451 or
miR-668 as a biomarker to differentiate the exposure to
Figure 4 Expression of miR-451, miR-668, miR-1902, and miR-1904 of serum and WBCs from C57BL/6 and Tlr2−/− mice from real-time
RT-PCR experiments 6 h after exposure to 100 μg of LTA or phosphate-buffered saline (PBS); **, P < 0.01 vs. control of C57BL/6 or
Tlr2−/−. (A) C57BL/6 mice receiving injection of PBS or LTA; (B) Tlr2−/− mice receiving injection of PBS or LTA; (C) C57BL/6 or Tlr2−/− mice upon
injection of LTA.
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ture of miR-1902 and miR-1904 may be useful in differ-
entiating infections caused by gram-positive bacteria to
those by gram-negative bacteria. In the mouse jejunum
infections with Eimeria papillata, miR-1902 expression
was able to serve as one of those biomarkers to reflectthe garlic treatment of this illness [19]. A study on
mouse-adapted avian influenza H9N2 with the mutation
as substitution of E627K in the PB2 protein confirmed
the E627K to be responsible for the higher virulence of
H5N1 in mice. The mutation PB2-E627K located on the
microRNAs binding site responsible for the altered
Figure 5 Expression of miR-451, miR-668, miR-1902, and miR-1904 of serum from C57BL/6 mice using real-time RT-PCR experiments
6 h after exposure to 10, 100, and 1000 μg LPS from Escherichia coli serotype 026:B6; *, P < 0.05 vs. control.
Hsieh et al. Journal of Biomedical Science 2013, 20:2 Page 8 of 10
http://www.jbiomedsci.com/content/20/1/2recognition of mmu-mir-1904 may explain why the mu-
tation of PB2-E627K play the key role in virulence to
mice [20]. In this study, the increased miR-1902 and miR-
1904 of the whole blood could only be found 6 h after
LTA treatment; however, using spiked-in cel-miR-39 as an
internal control, significant expression of miR-1902 and
miR-1904 in the serum may be detectable as early as 2 h
following exposure to LTA. We believed this phenomenon
is due to the disturbance of measurement by the cellular
component of the whole blood as well as the use of U6
snRNA as an internal control, since these up-regulated
miRNAs are located in the serum but not in the
WBCs and the U6 snRNA is not a good candidate as a
normalization control for miRNAs in the serum [21,22].
In our previous work, in TLR4 receptor knockout
mice, five of eight miRNAs (i.e. let-7d, miR-25, miR-92a,
miR-103, and miR-107) was significantly lower following
exposure to LPS, with unchanged levels of the other
three miRNAs [14]. However, in this study, higher ex-
pression of miR-451, miR-668, miR-1902, and miR-1904
in the serum were observed in Tlr2−/− against C57BL/6
mice following LTA injection. This observation indicated
that these 4 miRNAs were not induced directly by the
TLR2 signaling. Because most pathogens can engage
multiple TLRs, some authors speculate that those
miRNAs induced by TLR singalling may regulate the
strength, location, and timing of TLR responses and
avoid excess pro-inflammtory repsonses as a negative
feedback loop by targeting the TLR signaling molecules
and shutting down several TLR pathways [23]. In
addition, different expressed miRNAs may work together
to control the expression of TLR signal components [23].
Whether the higher expression of miR-451, miR-668,
miR-1902, and miR-1904 in the serum upon LTA stimula-
tion is due to lack of the repressed targets of negative feed-
back loop in Tlr2−/− mice is speculated but lack ofevidence so far and required further investigation and
validation.
When compared to those upon LPS treatment in our
previous work [14], the circulating miRNA signature
after LTA treatment in this study has some additional
limitations. First, LPS is a stronger stimulator than LTA
to induce the expression of circulating miRNAs, consid-
ering the up-regulated 8 miRNAs of the whole blood
showed approximately 5- to 12-fold increase in expres-
sion 6 h after 100 and 1000 μg LPS injection, these four
miRNAs (miR-451, miR-668, miR-1902, and miR-1904)
had a less prominent 2- to 6-fold increase upon LTA
treatment. LTA has a simpler structure that typically
consists of a polyglycerolphosphate (PGP) chain that is
linked via a glycolipid anchor to the bacterial membrane
[24]. There was a small difference between the chemical
structures of PGP-type LTA from different Gram-positive
bacteria. For example, additional N-acetylglucosamine
modifications of the hydroxyl groups at position C2 of
PGP chain are found in B. subtilis but not in the S. aureus
[25]. Although LTA is a major immunostimulating com-
ponent in the cell wall of Gram-positive bacteria, it is
expressed on not only pathogenic but also nonpathogenic
Gram-positive bacteria. LTAs from Staphylococcus aureus
(pathogenic), Bacillus subtilis (non-pathogenic), or Lacto-
bacillus plantarum (beneficial) carry differential potencies
in the stimulation of TLR2 and expression of inflamma-
tory cytokines [26] as well as nitric oxide signaling
pathway [27]. In this study, LTA from Bacillus subtilis
demonstrated a different expression to those from Strepto-
coccus faecalis and Staphylococcus aureus. However, with
a weaker stimulator for miRNA expression, the sensitivity
and specificity of complex miRNA expression in diagnosis
may be limited. Second, unlike TLR4 comprised by the
homogenous dimers, TLR2 is involved in the recognition
of a wide range of pathogen-associated molecular patterns
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including bacterial lipoproteins [28,29], and peptidoglycan
[30], albeit the latter for TLR2 signaling is still an issue of
debate [31]. This high versatility of ligand recognition by
TLR2 is possibly due to the ability of TLR2 to form
heterodimers with TLR1 or TLR6 [32]. Third, LTAs are
commonly referred to as membrane-associated poly-
mers characteristic of gram-positive bacteria, just as
lipopolysaccharides are believed to be ubiquitous among
gram-negative bacteria [24]. However, the number of
gram-positive bacteria now known to lack classical LTA
is steadily increasing [24,33], that may limit the use of
circulating miRNAs as the biomarkers for exposure to
Gram-positive bacteria.
Despite accumulating evidence of miRNAs in the cir-
culation, the origin, the composition, and the function of
these circulating extracellular miRNAs remains poorly
understood [34]. Although the expression of circulating
miRNAs is thought to reflect extrusion of miRNAs from
relevant remote tissues or organs or disease processes
[6], currently, little is known regarding the biologic roles
of these molecules at distant sites in the body [35].
Three sources of circulating miRNAs had been sug-
gested, including (1) passive leakage from broken cells
due to tissue injury, chronic inflammation, cell apoptosis
or necrosis, or from cells with a short half-life, such as
platelets; (2) active secretion via microvesicles, including
exosomes and shedding vesicles; (3) active secretion using
a microvesicle-free, RNA-binding protein-dependent path-
way, where a significant portion of circulating miRNAs
in plasma is associated with high-density lipoprotein
(HDL) [36], Argonaute2 (AGO2) [37,38], and another
RNA-binding protein, nucleophosmin 1 (NPM1) [39].
From this study and our previous work, although we had
identified different expression signature of the circulating
miRNAs following LPS and LTA exposure as promising
biomarkers at the very first step; however, further investi-
gation is required to understand the location of expressed
miRNAs in the circulation and to clarify their origins and
physiological roles.
Conclusions
A specific circulating miRNA signature was identified in
mice exposed to LTA. That expression profile is different
from those of mice exposed to LPS. Those circulating
miRNAs induced by LTA or LPS treatment may serve as
promising biomarkers for the differentiation between
exposures to Gram-positive or Gram-negative bacteria.
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